Effect of nicorandil combined with tongxinluo capsule on no-reflow high-risk myocardial infarction

RONG Hui; ZHENG Junliang; YUAN Min

Abstract：Objective:To explore the therapeutic effect of using nicorandil combined with xinluo capsules on high-risk myocardial infarction(AMI)patients without imminent reflow evaluated by Generalized Estimating Equations(GEE).Methods:A prospective study was conducted on 80 patients with high-risk AMI who were assessed by GEE in hospital as having no recurrent flow.The patients were selected from January 2021 to January 2023 and divided into two groups using a random number table method,40 cases in each group.The control group was treated with routine medicine,and the observation group was treated with nicorandil+tongxinluo capsule.The indexes of cardiac function and major cardiovascular events were observed 3 months after discharge.Results:Three months after discharge,the left ventricular ejection fraction(LVEF)of the observation group patients was higher than that of the control group,and the plasma brain natriuretic peptide(BNP)was lower than that of the control group(P＜0.05).The incidence of major cardiovascular events in the observation group 3 months after discharge was lower than that in the control group,but the comparison was not statistically significant(P＞0.05).Conclusion:Nicorandil combined with xinluo capsule in the treatment of AMI patients with high risk of no-reflow assessed by GEE can effectively improve cardiac function and reduce the incidence of major cardiovascular events in the near and long term.